StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark reiterated a “speculative buy” rating and set a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Performance

BIOLASE stock opened at $0.01 on Tuesday. The stock has a fifty day moving average of $0.01 and a 200 day moving average of $0.04. The stock has a market cap of $293,981.60, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a one year low of $0.02 and a one year high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.